UPB Stock Forecast & Price Target

Upstream Bio is viewed favorably because verekitug has produced strong Phase 2 efficacy across CRSwNP and severe asthma, including 79% of treated CRSwNP patients achieving clinically meaningful NPS improvement at Wk 24 and a 56% AAER reduction in severe asthma at 100mg every 12 weeks, with consistent safety and tolerability. The investment case is further strengthened by the drug’s differentiated TSLP-receptor mechanism, which may offer broader and deeper control than existing biologics while supporting convenient quarterly at-home dosing in a multi-billion-dollar respiratory market. Despite higher funding and execution risk, the asset appears de-risked with pivotal clarity expected in 2H26 and Phase 3 initiations in 1Q27, while the model implies probability-adjusted revenue rising to $1,285.5M by 2036.

Upstream Bio is viewed negatively because its lead asset verekitug has shown mixed durability across doses, with the 100mg quarterly regimen delivering about a 56% AAER reduction while the 400mg every-24-weeks regimen only achieved about 39%, raising questions about robustness and differentiation despite clinically meaningful FEV1 and FeNO improvements. The stock’s roughly -70% drop from $27.81 on February 10, 2026 to $8.33 on February 17, 2026 after positive Phase 2 VALIANT data suggests investors remain unconvinced, especially versus the less than 1% decline in XBI over the same period. Financially, limited cash runway, the capital intensity of Phase 3 asthma and CRSwNP programs, and an expected equity raise in 2H27 imply meaningful dilution and elevated financing risk, which is compounded by a higher 13% discount rate and insufficient resources to complete both programs.